Specifically, we evaluated RIP2 expression by mRNA FISH in stage-III breast cancer cases with either fewer than four axillary lymph nodes (N0, N1) or with significant axillary lymph node involvement (N3 or tumor metastasis in more than 10 axillary lymph nodes, infraclavicular lymph nodes, supraclavicular lymph nodes, or clinically detected ipsilateral internal mammary lymph nodes along with other axillary lymph nodes). The gene discussed is RIPK2; the disease is neoplasm.